17 of the 18 members of the FDA’s Vaccines and Related Biologicals Advisory Committee agreed that the benefits of Pfizer-BioNTech’s Covid-19 vaccine for primary school-aged children outweigh the risks.
At the meeting, it was mentioned that the company has reduced the Covid-19 vaccine for children under the age of 12 to one third of the adult dose.
The FDA is expected to consider the committee’s recommendation and issue immediate use approval for this vaccine within a week.
Pfizer-BioNTech announced on October 22 that the Covid-19 vaccine, which will be administered in two doses, provides more than 90 percent protection for children aged 5-11 years.
Vaccine advisors from the US Centers for Disease Control and Prevention (CDC) will meet on November 2 and 3 to discuss the decision and decide whether or not to recommend US children get vaccinated.
CDC Director Dr. It will be owned by Rochelle Walensky, and with her permission, vaccination can begin next week.
. (HAS) is published on the Anadolu Agency website, in summary. ..